Using Patents to Increase Profits and Secure Investment


Dr Greg StepneyPartner | EP and UK Patent Attorney - Withers & Rogers

Time & Location

Wednesday: 15.20 to 15.40, Stage 3

About this presentation

Patents are sometimes viewed simply as a necessary cost to protecting against the emergence of copycat products, a final barrier to entry for technology that can be reverse-engineered. Whilst true, patents enhance business in various other ways. This session will interactively discuss ways to increase the bottom line by using patents to slash corporation tax and secure vital investment for future expansion.

Speaker Bio:

Greg Stepney is a EP and UK Patent Attorney specialising in chemical inventions. He has worked with the full spectrum of chemical inventions over the course of his 13 year career. Some of the diverse fields in which he has helped clients include industrial-scale fine chemicals, pharmaceuticals, oil & gas, halocarbons, polymers, food and drink, agriculture, printing methods and inks, nonwoven materials, detergents, photochemistry, materials chemistry and batteries. The majority of Greg’s work is conducted at the European Patent Office, where he has a long and successful track record defending and attacking patents in opposition and opposition-appeal proceedings. Away from the EPO, Greg conducts patent prosecution and portfolio management in upwards of 70 countries, drafts new applications and provides advice relating to patent validity and infringement. Education & background Greg graduated from Loughborough University with a first class chemistry degree. He was then awarded a PhD in chemistry by the University of Nottingham for a thesis titled ‘Nitroalkenes as Latent Nucleophiles for the Nitro-Mannich Reaction’. He has also conducted research with GlaxoSmithKline, AstraZeneca and Pfizer. Greg entered the profession in 2007 and qualified as a patent attorney in 2012. He qualified as a European patent attorney with the 15th highest exam mark in Europe and his legal paper answer was selected by the EPO as that year’s model answer.